Global Drug Discovery Technologies & Products Market

Dallas, TX -- (SBWIRE) -- 06/14/2012 -- Report Highlights

1. The global market for drug discovery technologies and products reached $38.4 billion in 2011. It is expected to expand to $41.4 billion in 2012 and to $79.0 billion in 2017, a compound annual growth rate (CAGR) of 13.8% between 2012 and 2017.
2. The high-throughput screening market reached $11.0 billion in 2011. It is expected to expand to $11.5 billion in 2012 and to $20.0 billion in 2017, a CAGR of 11.7% between 2012 and 2017.
3. The bioanalytical instruments market for drug discovery reached $9.2 billion in 2011. It is expected to expand to $10.0 billion in 2012 and to $15.0 billion in 2017, a CAGR of 8.4% between 2012 and 2017.


STUDY GOALS AND OBJECTIVES

This market research report, Drug Discovery Technologies, provides an overview of the current state of the drug discovery market, existing platforms and products on the market, and detailed analysis of the competitive environments including new, potential venues for novel technologies and approaches. The study includes information about significant players in this field of study, trends and obstacles, and other information affecting development of new products, devices, and therapies in the drug discovery sector.

REASONS FOR DOING THIS STUDY

Drug discovery is one of the main sectors in the pharmaceutical industry. Drug development in general is a billion dollar industry and is highly dependent on its research and scientific advancement. Today, the process of drug discovery has become more systematic in comparison to the more physiological approaches in previous decades. In the current drug discovery market, the drug target is identified first, followed by a search for compounds or molecular entities that can inhibit or enhance its activity. Consequently, technology has a crucial impact on identification and validation of new drug candidates.

In general, the scientific and biotechnology community has seen many breakthrough technologies in the last decade. Surprisingly, there is a big gap between the initial introduction of new platforms and their further application and commercial success. Many analysts and industry insiders are trying to understand the reasons why, in spite of technological advancement, the pharmaceutical industry does not provide more successful drugs and why certain technologies fail to advance or accelerate the drug discovery process.

It is important to note that biological and pathological conditions are very complex. Therefore, in order to understand properly the effect of a technology or platform in drug discovery application, the market should be divided into main categories such as, for example, genomics or proteomics-based approaches and their related drug discovery technologies. Each sector has its novel trends and challenges that affect the drug discovery market in general and specific segments in particular.

Market participants vary among the different niches in the drug discovery industry. There is also a clear division between technology developers, manufacturer/ suppliers, and biotech companies. Each type of market participant has a different business strategy and is affected differently by positive or negative drivers discussed in this report.

In summary, this report will highlight the main aspects, sectors, and trends in the drug discovery technologies market, the major market participants, and the current and future trends in each sector. Drivers and challenges in each segment of the industry will be discussed in detail including forecasts for the next five years.

SCOPE AND FORMAT

This report represents a current and important business tool to evaluate new commercial opportunities in the drug discovery technology market. The geographic scope of this study covers the U.S., Europe, and companies worldwide. This market is complex and consists of a number of sectors, each affected differently by scientific and technological development. The report identifies main positive and negative factors in each sector and forecasts further trends, products, and technologies in every category of the industry.

Buy your copy of this report @ http://www.reportsnreports.com/reports/166222-drug-discovery-technologies.html . Contact sales@reportsandreports.com for further information.

LIST OF SELECT COMPANIES REPRESENTING THE DRUG DISCOVERY INDUSTRY

ACTIVE MOTIF
ADVANCED CELL TECHNOLOGY INC
AFFYMETRIX
ALDAGEN INC
ALNYLAM PHARMACEUTICALS
ASTRAZENECA PHARMACEUTICAL LP
AVIVA BIOSCIENCES CORP
AURORA BIOMED INC
BD BIOSCIENCES
BECKMAN COULTER INC.
BIO-RAD LABORATORIES
BIOMYX TECHNOLOGY
BIOVISION
BRUKER CORP.
BTX INSTRUMENT DIVISION
CALIPER LIFE SCIENCES
CAPRICOR INC
CELL BIOSCIENCES INC.
CELLCENTRIC LTD.
CELGENE CORP.
CEPHEID
CERES NANOSCIENCES
CHEMBRIDGE CORP.
CHEMDIV
CHENOMX
CLONTECH LABORATORIES
COMPLETE GENOMICS INC.
COMPUGEN LTD.
DEVELOGEN AG
DIGILAB INC.
ECHELON BIOSCIENCES INC.
EMD4BIOSCIENCES
EMERALD BIOSYSTEMS
EPIGENTEK GROUP INC.
EXIQON A/S
EVOTEC INC.
FLUIDIGM
GAMIDA CELL LTD.
GE HEALTHCARE U.K. LTD.
GENECRAFT
GENOMATICA
GILSON INC.
HIGH THROUGHPUT GENOMICS INC
F. HOFFMAN-LA ROCHE AG
KINEXUS BIOINFORMATICS CORP.
LI-COR
LIGON DISCOVERY
LIFE TECHNOLOGIES CORP.
MARINA BIOTECH
MAXCYTE INC.
METABOLON INC.
MILLIPORE (EMD GROUP) .
MOLECULAR DEVICES INC
NEURALSTEM
NEW ENGLAND BIOLABS
NEXTGEN SCIENCES INC.
OSIRIS THERAPEUTICS INC.
PERKIN-ELMER
PLURISTEM THERAPEUTICS INC.
PROMEGA CORP.
PROTAGEN AG
PROTEA BIOSCIENCES INC.
PROTEIN DISCOVERY INC.
PROTEOME SYSTEMS .
QIAGEN .
R&D SYSTEMS INC.
SHIMADZU CORP.
SIGMA-ALDRICH
STEMGENT
TECAN GROUP LTD.
THERMO FISHER SCIENTIFIC INC.
VIACYTE